72 Results for "

beta-arrestin2

" in MedChemExpress (MCE) Product Catalog:
Products (72)

72 Results for "beta-arrestin2" in MCE Product Catalog:

Cat. No.: HY-108656A
Purity:  ≥99.0%
Target:  

P2Y Receptor Arrestin

Research Areas:  

Cardiovascular Disease

MRS2365 trisodium is a potent and selective P2Y1 receptor (EC50=0.4 nM)/[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity [2] .
loading...
    loading...
Cat. No.: HY-106481
CAS No.: 54867-56-0
Purity:  95.16%
Research Areas:  

Inflammation/Immunology

Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide [2] .
loading...
    loading...
Cat. No.: HY-14299AR
CAS No.: 753498-25-8
Synonyms: QAB149 (Standard)
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research [2].
loading...
    loading...
Cat. No.: HY-110302
CAS No.: 2410327-94-3
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons .
loading...
    loading...
Cat. No.: HY-145278
CAS No.: 2752378-78-0
Purity:  99.82%
Target:  

RXFP Receptor

Research Areas:  

Neurological Disease

RXFP3/4 agonist 2 is a potent, nonpeptide dual RXFP3/4 agonist (EC50=3.1 and 2.7 nM). RXFP3/4 agonist 2 also potently promotes interactions between RXFP3 and β-arrestin-2 with EC50 values in the range of 10-22 nM .
loading...
    loading...
Cat. No.: HY-14299R
CAS No.: 312753-06-3
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research [2].
loading...
    loading...
Cat. No.: HY-175306
CAS No.: 2380033-51-0
Target:  

EBI2/GPR183 Arrestin

Research Areas:  

Inflammation/Immunology Cancer

GPR183 inverse agonist-1 (Compound 78) is a GPR183 inverse agonist. GPR183 inverse agonist-1 inhibits the GPR183-mediated Gi activation and β-arrestin2 recruitment, and blocks PBMC migration. GPR183 inverse agonist-1 can be used for inflammatory, autoimmune and neoplastic disorders research .
loading...
    loading...
Cat. No.: HY-P11237
CAS No.: 2869147-44-2
Synonyms: CT-388
Enicepatide (CT-388) is a cAMP signal-biased dual GLP-1R and GIPR agonist peptide, with an EC50 value of 0.087 nM for GLP-1R cAMP, and an EC50 value of 2.47 nM for GIPR cAMP. Enicepatide activates the cAMP signaling pathway, while recruiting only minimal amounts of β-arrestin-2 at both targets and reducing receptor internalization levels. Enicepatide improves glycemic control, reduces body weight, suppresses appetite, and ameliorates the pathological conditions of metabolic dysfunction-associated steatohepatitis. Enicepatide can be used in the research of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis .
loading...
    loading...
Cat. No.: HY-134092
CAS No.: 131391-65-6
Synonyms: N-Methyl-LTC4
N-Methyl Leukotriene C4 (N-Methyl-LTC4) is a non-metabolizable LTC4 analog and a selective cysteinyl leukotriene receptor 2 (CysLT2) agonist, with an EC50 of 46.1 nM for mouse CysLT2 and an EC50 value of 122.3 nM for human CysLT2. N-Methyl Leukotriene C4 shows low potency against CysLT1. N-Methyl Leukotriene C4 activates human and mouse CysLT2 receptors, triggering calcium signaling, β-arrestin-2 binding to phosphorylated receptors, vascular leakage, hypotension, tachycardia, contraction of guinea pig ileum and trachea, mild bronchoconstriction, as well as hypertension associated with peripheral vasoconstriction. N-Methyl Leukotriene C4 can be used in research on asthma, rhinitis, sinusitis, cerebral inflammation and edema, pulmonary arterial hypertension, and cardiovascular diseases [2] .
loading...
    loading...
Cat. No.: HY-107665
CAS No.: 62645-28-7
Ro 106-9920 is an orally active NF-κB inhibitor. Ro 106-9920 prevents ubiquitination of IκBα, blocks nuclear translocation of NF-κB, and inhibits NF-κB activation. Ro 106-9920 suppresses TNF-α-induced tissue factor expression and procoagulant activity, enhances TNF-α-mediated cytotoxicity against cancer cells, and eliminates the formation of neutrophil extracellular traps. Ro 106-9920 inhibits NLRP3 inflammasome activation, reduces inflammatory cytokine secretion, decreases myeloperoxidase activity, attenuates renal cell apoptosis, and improves renal function. Ro 106-9920 blocks ANG II (Angiotensin II human) (HY-13948)-induced nuclear localization of p65, internalization of AT1A receptor, colocalization of β-arrestin-2, and expression of COX-2, and alters the formation of β-arrestin endosomes. Ro 106-9920 can be used in research related to non-small cell lung cancer, acute kidney injury, diabetes mellitus, and osteoporosis [2] .
loading...
    loading...
Cat. No.: HY-179471
CAS No.: 2189700-03-4
Target:  

GPR84

Research Areas:  

Inflammation/Immunology

PSB-17365 is a potent GPR84 agonist with EC50 values of 2.5 nM and 100 nM in a cAMP accumulation assay and a β-arrestin 2 recruitment assay, respectively .
loading...
    loading...
Cat. No.: HY-157429
CAS No.: 2865185-31-3
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

25N-N1-Nap is a blood-brain barrier-permeable, selective, β-arrestin2-biased 5-HT2A receptor (5-HT2AR) agonist. 25N-N1-Nap reduces Gq efficacy while preserving β-arrestin2 efficacy. 25N-N1-Nap does not induce hallucinogen-like behavioral responses, blocks hyperactivity induced by hallucinogens and psychostimulants, and induces rapid tolerance to hallucinogen-like responses. 25N-N1-Nap can be used for research on schizophrenia-related hyperactivity [2].
loading...
    loading...
Cat. No.: HY-175366
CAS No.: 939956-07-7
Research Areas:  

Neurological Disease

DOR agonist 3 (Compound 10) is a δ-opioid receptor (DOR)-selective positive allosteric modulator. DOR agonist 3 enhances G protein signaling while reducing β-arrestin2 recruitment. DOR agonist 3 is promising for research of chronic pain and depression .
loading...
    loading...
Cat. No.: HY-113689
CAS No.: 102704-40-5
Purity:  99.98%
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC50 values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research .
loading...
    loading...
Cat. No.: HY-138951
CAS No.: 1835734-92-3
AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC50 of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca 2+ release [2].
loading...
    loading...
Cat. No.: HY-163277
Target:  

Opioid Receptor

Research Areas:  

Inflammation/Immunology

PIPE-3297 (compound 25) is a selective kappa opioid receptor (KOR) agonist, which activates the G-protein signaling with EC50 of 1.1 nM and exhibits low β-arrestin-2 recruitment activity (10%). PIPE-3297 induces myelination and reveals an anti-inflammatory activity .
loading...
    loading...
Cat. No.: HY-178203
CAS No.: 3054511-18-8
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

AM12814 is a potent and partial CB1 and CB2 agonist with Ki values of 0.7 nM and 3.4 nM. AM12814 can inhibit cAMP accumulation and recruitse β-arrestin 2. AM12814 exhibits cannabimimetic effects. AM12814 can be used for the research of neurological disease, suah as catalepsy .
loading...
    loading...
Cat. No.: HY-P1102A
Target:  

CXCR HIV

Research Areas:  

Infection Cancer

TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 TFA is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity [2].
loading...
    loading...
Cat. No.: HY-P3346
CAS No.: 2891469-80-8
Target:  

Apelin Receptor (APJ)

Research Areas:  

Cardiovascular Disease

NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) (compound 39) is a potent APJ agonist, with a Ki of 0.6 nM. NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) can activate Gαi1 (EC50=0.8 nM) and recruit β-arrestin2 (EC50=31 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal) exhibits prolonged cardiac effects .
loading...
    loading...
Cat. No.: HY-P11246
CAS No.: 3057097-31-8
Target:  

RXFP Receptor

Research Areas:  

Metabolic Disease

A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
loading...
    loading...